Breaking News, Collaborations & Alliances

Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic

Will conduct an immunohistochemistry study to accelerate HT-KIT.

Author Image

By: Charlie Sternberg

Associate Editor

Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer-fighting therapeutic, HT-KIT. HT-KIT, Hoth’s preclinical therapeutic candidate, targets c-Kit, a receptor tyrosine kinase implicated in numerous cancers. This candidate holds the potential to revolutionize precision oncology therapies. This immunohistochemistry study, conducted in partner...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics